Tuesday, December 22, 2020 5:55:47 PM
Recent OCGN News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2024 09:17:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 09:05:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 08:25:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 02:55:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 09:30:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 06:43:16 PM
- Ocugen Provides Business Update with Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/08/2024 11:45:51 AM
- Ocugen Secures $30 Million in Debt Funding • GlobeNewswire Inc. • 11/07/2024 11:30:55 AM
- Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 • GlobeNewswire Inc. • 10/28/2024 10:30:00 AM
- Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease • GlobeNewswire Inc. • 10/22/2024 11:02:15 AM
- Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 10/17/2024 11:30:11 AM
- Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial • GlobeNewswire Inc. • 10/09/2024 10:30:32 AM
- Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa • GlobeNewswire Inc. • 10/02/2024 10:30:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/26/2024 08:27:41 PM
- Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 09/24/2024 11:30:00 AM
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop • GlobeNewswire Inc. • 09/09/2024 10:30:12 AM
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit • GlobeNewswire Inc. • 09/05/2024 11:00:07 AM
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:30:42 AM
- Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 08/28/2024 10:30:32 AM
- Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 08/26/2024 11:02:41 AM
- Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading • PR Newswire (US) • 08/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/16/2024 08:16:42 PM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM